BIOMAT Database Logo BIOMAT Database Logo

Synthesis and biological activity of a new cephalosporin, BMY-28232 and its prodrug-type esters for oral use. 1988

H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Bristol-Myers Research Institute, Ltd., Tokyo Research Center, Japan.

The synthesis and structure-activity relationships of 7-[(Z)-2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido]-3-[( Z)-1- propenyl]-3-cephem-4-carboxylic acid (BMY-28232), its 3-alkenyl analogs (6 and 7) and O-substituted derivatives of the oxyimino moiety (10) are described, as well as the oral pharmacokinetics and in vivo activities of the 1-acetoxyethyl ester of BMY-28232 (BMY-28271) and its analogous esters (11). The 3-alkenyl groups were introduced by the Wittig reaction of the ylide (2) prepared from the 3-chloromethyl cephem (1) to afford the Z (main) and E (minor) isomers regarding the 3-side chain. The O-substituted derivatives (10) were prepared by 7-N-acylation of the 7-amino cephem (4a) with the corresponding O-substituted side chain acids (8). The prodrug esters (11) were prepared by esterification of BMY-28232 with an appropriate halide. BMY-28232 was the most active among the 3-alkenyl analogs tested against Gram-negative organisms and much more active than the O-substituted derivatives against Gram-positive bacteria. BMY-28271 showed good oral bioavailability (66%) and good in vivo efficacy in mice against infections of Staphylococcus aureus Smith (PD50, 0.68 mg/kg) and Escherichia coli Juhl (0.54 mg/kg).

UI MeSH Term Description Entries
D008297 Male Males
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004952 Esters Compounds derived from organic or inorganic acids in which at least one hydroxyl group is replaced by an –O-alkyl or another organic group. They can be represented by the structure formula RCOOR’ and are usually formed by the reaction between an acid and an alcohol with elimination of water. Ester
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
In vitro and in vivo evaluations of a new broad-spectrum oral cephalosporin, BMY-28232, and its prodrug esters.
April 1989, Antimicrobial agents and chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Antimicrobial activity and beta-lactamase stability of BMY-28232, parent compound of an oral cephalosporin.
November 1990, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
BMY 28100, a new oral cephalosporin.
February 1987, Antimicrobial agents and chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
In vitro activity of BMY-28100, a new oral cephalosporin.
April 1987, Antimicrobial agents and chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
In vitro activity of BMY-28100, a new oral cephalosporin.
January 1988, Chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.
March 1987, Antimicrobial agents and chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
In vitro activity of BMY 28100, a new oral cephalosporin.
February 1987, European journal of clinical microbiology,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Synthesis and structure-activity relationships of a new oral cephalosporin, BMY-28100 and related compounds.
July 1987, The Journal of antibiotics,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Preliminary in-vitro studies of BMY-28232, the active metabolite of the BMY-28271 cephalosporin ester.
April 1989, The Journal of antimicrobial chemotherapy,
H Kamachi, and Y Narita, and T Okita, and Y Abe, and S Iimura, and K Tomatsu, and T Yamasaki, and J Okumura, and T Naito, and T Oki
Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
June 1987, European journal of clinical microbiology,
Copied contents to your clipboard!